Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist.

@article{Dittrich2005EndocrineTO,
  title={Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist.},
  author={Ralf Dittrich and Helge Binder and Susanne Cupisti and Inge Hoffmann and M. W. Beckmann and Andressa Mueller},
  journal={Experimental and clinical endocrinology \& diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association},
  year={2005},
  volume={113 10},
  pages={
          586-92
        }
}
  • R. Dittrich, H. Binder, +3 authors A. Mueller
  • Published 2005
  • Medicine
  • Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
In transsexual people, cross-sex hormone therapy is an important component of medical treatment. In male-to-female transsexuals, feminizing effects should be achieved before irreversible sex reassignment surgery (SRS) is considered. The most common treatment regimen in male-to-female transsexuals is a combination of ethinyl oestradiol and cyproterone acetate, with the exception of transdermal oestradiol-17beta in individuals over the age of 40. The mortality and morbidity rates with this… Expand
Effects of transdermal testosterone or oral dydrogesterone on hypoactive sexual desire disorder in transsexual women: results of a pilot study.
TLDR
In this pilot study, sexual desire in transsexual women improved significantly after treatment with the testosterone patch, without noticeable side effects. Expand
Efficacy of Sex Steroid Therapy without Progestin or GnRH Agonist for Gonadal Suppression in Adult Transgender Patients.
TLDR
T and E2 therapy are usually effective without progestin or GnRHa therapy to suppress gonadal function in transgender patients and should only be initiated in those patients who do not have adequate gonadal suppression on optimized doses of T or E2 alone. Expand
Long-term administration of testosterone undecanoate every 3 months for testosterone supplementation in female-to-male transsexuals.
TLDR
The treatment of female-to-male transsexuals with long-acting testosterone undecanoate may be a feasible and safe option for testosterone augmentation in these subjects, however, monitoring of blood pressure should not be ignored during the treatment, to identify patients liable to develop hypertension. Expand
A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones.
TLDR
The increased mortality in hormone-treated MtF transsexuals was mainly due to non-hormone-related causes, but ethinyl estradiol may increase the risk of cardiovascular death, and use of testosterone in doses used for hypogonadal men seemed safe. Expand
Body composition and bone mineral density in male-to-female transsexuals during cross-sex hormone therapy using gonadotrophin-releasing hormone agonist.
  • A. Mueller, H. Zollver, +5 authors R. Dittrich
  • Medicine
  • Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
  • 2011
TLDR
There appears to be no risk of osteoporosis developing in MtFs when there is adequate oestrogen substitution, even in the absence of testosterone, and the complication rates appear to be lower in patients receiving gonadotrophin-releasing hormone agonists and intramuscular oestrogens. Expand
Long-term evaluation of cross-sex hormone treatment in transsexual persons.
TLDR
Cross-sex hormone treatment appears to be safe in transsexual men, but a substantial number of transsexual women suffered from osteoporosis at the lumbar spine and distal arm, and more attention should be paid to decrease cardiovascular risk factors during hormone therapy management. Expand
Venous thrombo‐embolism as a complication of cross‐sex hormone treatment of male‐to‐female transsexual subjects: a review
TLDR
It seems advisable to stop hormone use at least 2 weeks before major surgery, to be resumed only after 3 weeks following full mobilisation, and other oral oestrogens should not be overdosed, and transdermal oestrogen is to be preferred. Expand
Oestrogen and anti-androgen therapy for transgender women.
TLDR
The evidence base for the care of transgender women is limited by the paucity of high-quality research, and long-term longitudinal studies are needed to inform future guidelines. Expand
Low bone mass is prevalent in male-to-female transsexual persons before the start of cross-sex hormonal therapy and gonadectomy.
TLDR
Transsexual women before the start of hormonal therapy appear to have lower muscle mass and strength and lower bone mass compared with control men, which might be related to a less active lifestyle. Expand
Recommendations of endocrine treatment for patients with gender dysphoria
TLDR
An objective and independent review of all published papers providing clinical guidelines in the hormonal and medical care of patients with gender dysphoria and transsexualism is provided to suggest safe modern prescribing guidelines. Expand
...
1
2
3
4
5
...